<DOC>
	<DOC>NCT01017302</DOC>
	<brief_summary>This randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO5095932 in adult patients with type 2 diabetes mellitus. Patients that are on stable metformin therapy are eligible to enter the study. There will be a 5-weeks exenatide run in period and a 5-weeks period when co-administered with the study drug. RO5095932 will be administered subcutaneously as a single dose or as escalating doses. Patients will be randomized to receive either active drug or placebo in weeks 1 to 4. Active drug or placebo will be administered once weekly for 4 weeks. Patients who received active drug in weeks 1 to 4 will receive placebo in week 5. Patients who received a single dose of placebo in weeks 1 to 4, will receive a single dose of active drug in week 5. The anticipated time of study treatment is &lt;6 months. The target sample size is &lt;100 patients.</brief_summary>
	<brief_title>A Study With RO5095932 in Patients With Type 2 Diabetes on Stable Metformin Therapy.</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Adult patients, 1865 years of age Diabetes mellitus, type 2 for at least 6 months before screening On treatment with stable doses of metformin for at least 3 months before screening BMI between &gt;/=25 and &lt;/=39 Type 1 diabetes Pancreatitis Treatment with insulin for more than one week within 3 months prior to study start</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>